Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244981 | 0.85 | DUT (0.41) | DUTPARP1PARP2 | |
| SCHEMBL5244775 | 0.72 | DUT (0.37) | DUT | |
| SCHEMBL3536122 | 0.71 | DUT (0.49) | DUTPARP1PARP2 | |
| SCHEMBL28523658 | 0.71 | DUT (0.46) | DUT | |
| SCHEMBL6161985 | 0.71 | DUT (0.43) | DUTPARP1PARP2 | |
| SCHEMBL1632352 | 0.70 | DUT (0.45) | DUTPARP1PARP2 | |
| SCHEMBL8865301 | 0.70 | DUT (0.44) | DUTPARP1PARP2 | |
| SCHEMBL28437904 | 0.68 | DUT (0.46) | DUTPARP1PARP2 | |
| SCHEMBL21389208 | 0.67 | DUT (0.38) | DUT | |
| SCHEMBL1633091 | 0.67 | DUT (0.41) | DUTPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137325-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683173-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090076026-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-19 | — | — | US | disclosed |
| US-7479562-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| EP-1856049-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006099031-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205946-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects of dry-mouth and constipation; biphenyl carbamate derivatives; biphenyl-2-ylcarbamic acid 1-(3-(3-[3-(4-hydroxybenzylamino)propyl]-2-oxoimidazolidin-1-yl)propyl)piperidin-4-yl ester | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076026-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | DUT 2401/4885PARP1 3627/4885PARP2 3434/4885 |
| US-20100137325-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | DUT 2401/4885PARP1 3627/4885PARP2 3434/4885 |
| US-20060205946-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects of dry-mouth and constipation; biphenyl carbamate derivatives; biphenyl-2-ylcarbamic acid 1-(3-(3-[3-(4-hydroxybenzylamino)propyl]-2-oxoimidazolidin-1-yl)propyl)piperidin-4-yl ester | CHRM3, CHRM2, CHRM1 | DUT 1652/4885PARP1 2451/4885PARP2 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.